Mast Therapeutics, Inc.(MSTX)- NYSEMKT
  • Wed, Feb. 10, 9:37 AM
    • Mast Therapeutics (MSTX -40.2%) prices its public offering of 29,090,910 units at $0.275 per unit. Each unit consists of one share of common stock and one five-year warrant to purchase one share of common at $0.42. Net proceeds will be ~$7.3M. Closing date is February 16.
    • Net proceeds will fund the clinical development and commercialization of vepoloxamer, working capital and general corporate purposes.
    • Previously: Mast initiates equity offering (Feb. 9)
    | Wed, Feb. 10, 9:37 AM | 3 Comments
  • Sep. 8, 2014, 10:02 AM
    • Shares of Mast Therapeutics (MSTX +7%) jump in response to its report of positive results from a Phase 2 clinical trial evaluating the safety and efficacy of AIR001 (sodium nitrite) for the treatment of patients with pulmonary arterial hypertension (PAH). In the primary efficacy analysis, all doses showed improvement in median vascular resistance (PVR). In the secondary efficacy analysis, all doses showed improvements in the median distances achieved in the 6-minute walk test, including clinically-meaningful improvements at the highest dose level. Whether the results are statistically significant is unknown.
    • Methemoglobin levels remained normal (<1.5%) which is a positive since elevated levels are associated with IV-administered nitrite.
    • Mast obtained the rights to AIR001 from its acquisition of privately-held Aires Pharmaceuticals in February of this year.
    • The study was powered to enroll 90 patients but Aires discontinued enrollment due to the lack of capital. The reported data is from 29 subjects.
    | Sep. 8, 2014, 10:02 AM
  • Mar. 26, 2014, 9:03 AM
    • Mast Therapeutics (MSTX) initiates a Phase II study of MST-188 in patients with acute lower-limb ischemia, which is a complication of peripheral arterial disease that can lead to a limb being amputated and even death. (PR)
    • Shares are +8.3%.
    • Q4 Earnings
    | Mar. 26, 2014, 9:03 AM
  • Feb. 10, 2014, 9:36 AM
    • Mast Therapeutics (MSTX) has agreed to acquire Aires Pharmaceuticals, a privately held clinical-stage company developing therapies for pulmonary vascular disorders, in an all-stock deal.
    • Aires' lead product, AIR001, has orphan-drug status in the U.S. and Europe for pulmonary arterial hypertension.
    • Under the terms of the transaction, Aires will receive shares representing 6% of Mast's commons stock.
    • Adam Feuerstein tweets that Mast is "paying 6M shares of stock for Aires, or roughly $5M." Feuerstein also notes that Novartis had an option to acquire Aires but has apparently decided not to take it.
    • Notwithstanding, Mast's shares are +5%. (PR)
    | Feb. 10, 2014, 9:36 AM
  • Jan. 13, 2014, 4:04 PM
    • Mast Therapeutics (MSTX) — which got some traction earlier this month after saying MST-188 "demonstrated a statistically significant improvement in numerous parameters of heart function," in a nonclinical heart failure model — closes the day with a 57% gain.
    • Earlier, a trader purchased some 4K July $1 calls — volume in that strike was triple the existing open interest, according to OptionMonster.
    | Jan. 13, 2014, 4:04 PM | 2 Comments
  • Jan. 6, 2014, 8:51 AM
    • Mast Therapeutics (MSTX) is up 12% in early action.
    • The company says MST-188 "demonstrated a statistically significant improvement in numerous parameters of heart function," in a nonclinical heart failure model.
    • The data collected suggest the treatment may be promising way to improve left ventricular ejection fraction and end-systolic volume.
    • The company intends to "provide an update on its plans for MST-188 in heart failure later in 2014." (PR)
    | Jan. 6, 2014, 8:51 AM | 1 Comment
  • Oct. 3, 2013, 9:37 AM
    • Canaccord starts Mast Therapeutics (MSTX +15%) at Buy.
    • Analyst Ritu Baral likes MST-188's (Orphan designation in Europe) chances in sickle cell, and says EPIC "is well designed enough to to support FDA and EMA approval by itself if ... successful." Expect read-out in 2016.
    • Baral sees U.S. market launch in 2017 and peak sales of around $400M by 2023.
    • Price target is $3, which, even counting this morning's double-digit gains, translates into a 477% upside.
    | Oct. 3, 2013, 9:37 AM
  • Jun. 14, 2013, 2:04 PM

    Mast Therapeutics (MSTX -33.3%) tumbles after announcing the pricing of its 50M unit public offering. The units are offered at $0.50/each and come with one share of common and a warrant to purchase a half a share. The warrants and shares will be issued separately but purchased together. The exercise price on the warrants is $0.65. (PR)

    | Jun. 14, 2013, 2:04 PM
  • Jun. 13, 2013, 11:34 AM
    Mast Therapeutics (MSTX +1%) raises the size of its secondary to $34.5M from its initial offering of $30M.
    | Jun. 13, 2013, 11:34 AM
  • Mar. 25, 2013, 1:34 PM

    Mast Therapeutics (MSTX +1.4%) gains today after the European Commission granted orphan-drug designation to it's MST-188 drug candidate, a potential treatment for sickle cell disease. The decision gives MSTX 10 years of marketing exclusivity, and follows a similar positive opinion by the Committee for Orphan Medicinal Products. The company says it expects to now pursue strategic alliances "more aggressively."

    | Mar. 25, 2013, 1:34 PM | 1 Comment
  • Feb. 11, 2013, 3:19 PM

    Adventrx Pharmaceuticals (ANX -3%) says it's commenced dosing in its QT/QTc study of ANX-188. The study will assess whether or not the drug has an effect on QT prolongation, which can potentially lead to malignant cardiac rhythm disturbances, as part of an FDA requirement to assess cardiac repolarization for most new drugs having systemic bioavailability. The dosing is expected to be completed in the first quarter, and results ae anticipated in the second quarter of 2013.

    | Feb. 11, 2013, 3:19 PM
  • Jan. 30, 2013, 10:51 AM

    Microcap biopharmaceutical researcher Adventrx Pharmaceuticals (ANX +11.2%) gets a pop today after announcing that it's initiated patient recruitment for its Phase 3 clinical study of ANX-188 in sickle cell disease. Santosh Vetticaden, the company's Chief Medical Officer, says the drug "has the potential to be the first FDA-approved product for sickle cell disease vaso-occlusive crisis in fifteen years."

    | Jan. 30, 2013, 10:51 AM
  • Oct. 3, 2011, 12:26 PM

    Microcap bioresearch firm Adventrx Pharmaceuticals (ANX -1.1%) is lower today after the FDA says the company will need to repeat a study of its lung-cancer treatment Exelbine because it can't verify the authenticity of certain drugs in the previous trial. The shares have been pummeled this year, down nearly 78% since mid-July.

    | Oct. 3, 2011, 12:26 PM
  • Aug. 30, 2011, 12:46 PM

    Adventrx Pharmaceuticals (ANX +12%) pops after saying it's arranged a meeting with the FDA to discuss the approval of three late-stage pipeline products: ANX-514, ANX-188 and Exelbine.

    | Aug. 30, 2011, 12:46 PM
  • Aug. 10, 2011, 2:51 PM

    Microcap Adventrx Pharmaceuticals (ANX) shares plummet -56% after the FDA rejects a new application for the development-stage drug maker's lung-cancer treatment Exelbine. The agency says the authenticity of the drug products used in its pivotal bioequivalence trial could not be verified.

    | Aug. 10, 2011, 2:51 PM
Company Description
Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It provides products MST-188 has cytoprotective and hemorheologic properties and inhibits inflammatory processes and... More
Sector: Healthcare
Industry: Biotechnology
Country: United States